Phinmo 0,5 0,5 mg Capsule
PDF Leaflet Revision Date: 13 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Disease modifying therapy for relapsing multiple sclerosis.
Dosage (summary)
1 capsule (0.5 mg) orally once daily.
Onset of Action / Duration
Onset: 6 hours, Duration: 1 month
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Diabetic patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic in animals.
Key Drug Interactions
- Anti-dysrhythmic medicines
- CYP450 inducers
- Beta blockers
Contraindications
- Hypersensitivity to fingolimod
- Pregnancy and lactation
- Recent myocardial infarction
- Severe cardiac dysrhythmias
Common side effects
- Headache
- Diarrhoea
- Bradycardia
- Macular oedema
Counselling Points
- Monitor for signs of bradycardia after first dose.
- Use effective contraception during treatment.
- Report any signs of infection immediately.
Serious warnings
- Risk of bradydysrhythmia
- Increased risk of infections
- Potential for PML
Important Disclaimer
The Phinmo 0,5 0,5 mg Capsule professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
